Innovative Technology Acquisition Corporation Completes Acquisition of BioSource Therapeutics, Inc.: BioSource Therapeutics is a developer of nutritional supplements that address chronic nutritional issues in patients resulting from diseases such as HIV/AIDS, Cancer and Hepatitis

Busniess Wire - November 6, 2002

NEW YORK--(BUSINESS WIRE)--Nov. 6, 2002-- Innovative Technology Acquisition Corporation (OTCBB:ITAQ) has acquired 100 percent of BioSource Therapeutics, Inc. (BST), a life science biotechnology corporation dedicated to the research and development of innovative dietary supplements that address the effects of epidemic viral infections. BST is currently developing a product that addresses the needs of people with catabolic caexiea, commonly referred to as "wasting syndrome" related to diseases such as HIV/AIDS, Hepatitis and Cancer.

"The acquisition of BioSource Therapeutics is a positive step forward for the company," said Randy Lebow, President of Innovative Technology Acquisition Corporation. "The dietary supplement that BST is currently developing is intended to address the immunological considerations of progressive weight loss in chronic morbid disease management. The product is intended to be eligible for insurance reimbursement, and the Company will immediately seek approvals in key states, targeting Medicaid populations. The Company's strategic plan is on target, and we anticipate having product available and generating sales and revenues in the first quarter of 2003."

According to the AIDS Nutrition Services Alliance "Proper nutrition is a powerful tool for the successful management of HIV disease. Medical research confirms that weight loss - especially muscle tissue wasting - often leads to malnutrition and is a fatal manifestation of AIDS. Malnutrition has also been identified as a distinct cofactor contributing to HIV disease progression. In cases where new treatments prolong the lives of people living with HIV/AIDS, long-term survivors will benefit substantially from proper nutrition."

BioSource Therapeutics, Inc. is a research and development company that brings the latest cutting-edge biotechnologies together to create nutraceutical products that provide nutritional supplement solutions for people with debilitating, chronic diseases. BST is pioneering in the emerging scientific field of nutritional supplements to support traditional medical treatments and therapies.

Innovative Technology Acquisition Corporation identifies and acquires new nutraceutical products and companies with promising growth potential.

Statements made in this news release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of product development programs, the regulatory approval process, competitive products, and future capital requirements. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results such as, but not limited to: the ability of the Company to raise necessary capital; to attract and retain effective management; the lack of regulatory approvals or the failure of third-party contractors to perform their contractual obligations. Prospective investors are also referred to the other risks identified from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission

CONTACT: Gemini Integrated Financial Services,

Fort Lauderdale, Fla.

Jonathan Leinwand, 954/563-1583

SOURCE: Innovative Technology Acquisition Corporation

021106
BW021103

Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .